Southern Capital Advisors LLC Has $4.76 Million Position in iShares Biotechnology ETF $IBB

Southern Capital Advisors LLC grew its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 20.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,186 shares of the financial services provider’s stock after purchasing an additional 4,833 shares during the period. iShares Biotechnology ETF makes up 2.2% of Southern Capital Advisors LLC’s portfolio, making the stock its 12th biggest position. Southern Capital Advisors LLC owned about 0.06% of iShares Biotechnology ETF worth $4,759,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of IBB. Allspring Global Investments Holdings LLC lifted its position in shares of iShares Biotechnology ETF by 46,806.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 46,906 shares of the financial services provider’s stock worth $7,927,000 after purchasing an additional 46,806 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in iShares Biotechnology ETF during the third quarter valued at approximately $1,907,000. Tudor Investment Corp ET AL purchased a new position in iShares Biotechnology ETF during the third quarter valued at approximately $931,000. Central Pacific Bank Trust Division increased its stake in iShares Biotechnology ETF by 296,500.0% in the 4th quarter. Central Pacific Bank Trust Division now owns 14,830 shares of the financial services provider’s stock valued at $2,503,000 after buying an additional 14,825 shares during the period. Finally, WorthPointe LLC acquired a new position in iShares Biotechnology ETF in the 4th quarter valued at approximately $1,424,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

IBB stock opened at $173.64 on Monday. iShares Biotechnology ETF has a 12-month low of $123.61 and a 12-month high of $179.64. The company has a 50 day moving average of $170.61 and a two-hundred day moving average of $170.67.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Monday, June 15th were paid a $0.0238 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.1%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.